ArticleApplied microbiology and biotechnology2026
Alluvial filtration as a scalable and safe single-use technology for the harvest of viral vectors.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in gene therapy have increased the demand for large-scale manufacturing processes. The production of recombinant adeno-associated viral (rAAV) vectors, the predominant vectors used for gene delivery, requires efficient scalable processes for production and purification which have to comply with high safety standards. To enable operation in a fully closed system, the exclusive use of single-use materials and equipment is indispensable. The present study reports on the use of alluvial filtration for the clarification of lysed rAAV vector production culture from various production scales. In small-scale experiments (1-3 L feed), the in-house developed method was superior to the use of a synthetic depth filter regarding clarification performance for capacity, turbidity reduction, product recovery, and impurity reduction. Scale-up calculations for 500 L harvest revealed that alluvial filtration could provide the required filter area and capacity within a fully closed system, whereas the use of the depth filter could not. Real-life scale-up data for processing 10 L, 100 L, and 500 L with different rAAV vector variants confirmed scalability of the alluvial filtration method and yielded excellent results regarding its clarification performance. Moreover, the full filter capacity and limits of the system were not reached, indicating the robustness of the process to varying feedstock compositions. The safety of the established alluvial filtration train was supported by implementing enhanced monitoring and control to mitigate the risk of failure and leakages. Overall, the harvest of rAAV vectors by alluvial filtration proved to be superior to established depth filters within a biopharmaceutical production process. KEY POINTS: • Large-scale viral vector production (> 100 L) to meet increasing gene therapy demand • Alluvial filtration outperforms depth filters in efficient harvest clarification • Alluvial filtration offers capacity for closed-system scale-up to 500 L production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.